Uscom Limited Release: New Uscom BP+ Distributor In Vietnam

Sydney, Australia: 14th June 2016: Uscom (ASX code: UCM) (the Company or Uscom), a revenue stage, cardiovascular and pulmonary health technology company, today announced to market the appointment of Pozitronics of Hanoi as distributor of the Uscom BP+ and BP+ Reporter for Vietnam.

This appointment follows a state visit by the Vietnamese Minister for Health, the Head of the Department of Health, and a trade delegation of Vietnamese Health officials to the Uscom head office in Sydney six weeks ago. During the visit the delegation reviewed all the Uscom devices including the USCOM 1A, the BP+ and the SpiroSonic devices, and toured the Sydney manufacturing operations. The sale of BP+ and BP+Reporter into Vietnam will begin following the approval by the Vietnamese health regulatory authority.

During the visit the Ministers discussed with Uscom staff the opportunities for Uscom technologies to contribute to the health of Vietnam, and in particular the application of the USCOM 1A in the fight against Dengue and sepsis in adults and children. Pozitronics currently distribute the USCOM 1A through Pacific Medical Systems in Hong Kong.

Uscom CEO Associate Professor Rob Phillips said, “Vietnam is a rapidly growing, developing nation with an increasing focus on health and health care. The relationships we developed during the Health Minister’s visit have resulted in this new distribution appointment. Uscom has been selling USCOM 1As into Vietnam for a number of years through Pacific Medical Systems from Hong Kong. With Pozitronic now also distributing the BP+ we see a real opportunity to be a part of this rapidly expanding market. We anticipate the SpiroSonic range of devices will also be distributed into Vietnam when released later in the year.”

Vietnam has a population of 94m, and a GDP of $186b USD with a growth rate of approximately 6.5%, and a health spend of 7.1% of GDP pa ($13b USD) with more than 50% of its population covered by health insurance, and an ambition to grow this to more than 80% by 2020.

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis, guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD medications.

Reference: http://www.uscom.com.au/blog/1610/

About Uscom

Uscom Limited (UCM) is an ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A, Uscom BP+ and the Uscom SpiroSonic spirometers. All Uscom devices are premium resolution, and deploy innovative and practice leading technologies with FDA, CE, CFDA and TGA regulatory approval, and which are currently being marketed into global distribution networks.

The USCOM 1A is a simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotrope and vasoactive cardiovascular therapy.

The Uscom BP+ is a supra-systolic oscillometric Central Blood Pressure monitor which measures blood pressure and blood pressure waveforms only previously available using cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension, heart failure, intensive care, general practice and home care.

Uscom SpiroSonic digital ultrasonic spirometers are high fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial diseases and monitoring of pulmonary therapeutic compliance.

For more information, please visit: www.uscom.com.au

Back to news